Avian metapneumovirus (aMPV) and Newcastle disease virus (NDV) are threatening avian pathogens that can cause serious respiratory diseases in poultry worldwide. Vaccination, combined with strict biosecurity practices, has been the recommendation for controlling these diseases in the field. In the present study, we generated NDV LaSota vaccine strain-based recombinant viruses expressing the glycoprotein (G) of aMPV, subtype A or B, using reverse genetics technology. These recombinant viruses, rLS/aMPV-A G and rLS/aMPV-B G, were characterized in cell cultures and evaluated in turkeys as bivalent, next-generation vaccines. The results showed that these recombinant vaccine candidates were slightly attenuated in vivo, yet maintained similar growth dynamics, cytopathic effects, and virus titers in vitro when compared to the parental LaSota virus. The expression of the aMPV G protein in recombinant virus-infected cells was detected by immunofluorescence. Vaccination of turkeys with rLS/aMPV-A G or rLS/aMPV-B G conferred complete protection against velogenic NDV, CA02 strain challenge and partial protection against homologous pathogenic aMPV challenge. These results suggest that the LaSota recombinant virus is a safe and effective vaccine vector and expression of the G protein alone is not sufficient to provide full protection against aMPV-A or -B infections. Expression of other aMPV-A or -B virus immunogenic protein(s) individually or in conjunction with the G protein may be necessary to induce stronger and more protective immunity against aMPV diseases.
Introduction
Avian metapneumovirus (aMPV) is the causative agent for turkey rhinotracheitis (TRT) and is associated with "swollen head syndrome (SHS)" in chickens, resulting in substantial economic losses to the poultry industry worldwide [1, 2] . Isolates of aMPV have been classified into four subtypes, A, B, C, and D, based on the level of genetic variations and antigenic differences [2] . The aMPV subtypes A and B are present worldwide, excluding the USA; C is present mainly in the USA, France, and Korea [3, 4] ; and D has only been reported in France [5] .
In European and South American countries, cell cul-ture-attenuated or inactivated vaccines are currently being used to control the diseases caused by the subtypes A and B of aMPV [6] [7] [8] . Although these live, attenuated vaccines have been approved and appear to be effective in most countries where the disease is prevalent, several reports have suggested that the stability and safety of some of these live vaccines are of concern [9-12]. Recently in Italy [12] and Brazil [13] , field evidence has suggested that the existing vaccines may not fully protect against the circulating field strains of aMPV in these countries. To overcome the problems associated with vaccine safety and stability, efforts have been made to develop inactivated, subunit, virosomal, vectored, or genetically engineered vaccines [14] [15] [16] [17] [18] [19] [20] [21] . In contrast to live Protection by Recombinant Newcastle Disease Viruses (NDV) Expressing the Glycoprotein (G) of Avian Metapneumovirus (aMPV) Subtype A or B against Challenge with Virulent NDV and aMPV 131 attenuated vaccine, inactivated vaccines are potentially safer, but their protective efficacy remains controversial [14, 17] . Experimental subunit or vectored vaccines induced varying degrees of protective immunity during clinical trials [15, 16, 18, 21] . However, the administration of these non-conventional vaccines may not be practical to large commercial poultry operations. Newcastle disease virus (NDV) is the etiological agent of Newcastle disease, one of the most serious infectious diseases in poultry. All known strains of NDV are of a single serotype, but have been classified into three different virus pathotypes: velogenic (highly virulent), mesogenic (moderately virulent), and lentogenic (low virulence) [22] . Naturally-occurring lentogenic NDV strains, such as B1, VG/GA, and LaSota strains, are routinely used as live vaccines throughout the world to prevent Newcastle disease [22, 23] . These live vaccines induce both strong local and systemic responses and can be readily administered through drinking water supplies or by directly spraying the birds. During the past decade, recombinant NDV viruses have been developed as shuttle-vectors that express foreign antigens, such as avian influenza hemagglutinin (HA) protein, infectious bursal disease virus VP2 protein, and aMPV-C G protein, to protect poultry against NDV and the targeted avian pathogen [24] [25] [26] [27] [28] .
In this study, we generated LaSota vaccine strainbased recombinant NDV viruses expressing the major surface attachment glycoprotein (G) of aMPV-A or -B using reverse genetics techniques. We evaluated these recombinant viruses in vitro and in vivo for safety, stability, and expression of the G protein for their potential use as bivalent vaccines against NDV and aMPV-A or -B diseases.
Materials and Methods

Cells, Viruses and RNA Preparation
HEp-2 (CCL-81; ATCC) and DF-1 (CRL-12203; ATCC) cell lines were grown in Dulbecco's Modified Eagle Medium (DMEM, Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS, Invitrogen) and antibiotics. The DF-1 cells were maintained at 37˚C and 5% CO 2 in DMEM supplemented with 10% allantoic fluid (AF) from 10-day-old specific-pathogen-free (SPF) chicken embryos for all subsequent infections unless otherwise indicated. The NDV LaSota strain was obtained from ATCC and propagated in 9-day-old SPF chicken embryos. The cell culture-adapted strains of aMPV-A (UK, CVL 14/1) and aMPV-B (Hungary, 657/4) and the velogenic strain of NDV, California 2002 (NDV/CA02; game chicken/US(CA)/S0212676/02) were obtained from the pathogen repository bank at the Southeast Poultry Research Laboratory (SEPRL, USDA-ARS, Athens, GA, USA). The pathogenic aMPV-A and -B viruses were obtained from Dr. Kannan Ganapathy (University of Liverpool, UK) and the viruses were prepared from tracheal tissue of virus-infected SPF turkeys as challenge virus stocks and titrated in SPF turkeys for 50% infective dose (ID 50 ) as described previously [29] .
Viral RNA was extracted from either AF from NDVinfected chicken embryos or DF-1 cells using the TRIzol-LS reagent according to the manufacturer's instructions (Invitrogen). Total cellular RNA from tracheal tissues was extracted using the MagMAX™ AI/ND Viral RNA Isolation kit (ABI, Austin, TX) following the manufacturer's procedures.
Construction of Recombinant LaSota cDNA Clones Containing the G Gene of aMPV-A or -B
The infectious LaSota clone (pFLC-LaSota) and subclone (pT-LS MF) were previously generated [30] and used as backbones to construct recombinant cDNA clones containing the G gene of aMPV-A or -B (Figure 1) . The open reading frame (ORF) of the G gene of aMPV-A (UK, 14/1) or -B (Hungary, 567/4) was generated by RT-PCR amplification from genomic RNA with paired specific primers using a Superscript TM III One
Step RT-PCR system with Platinum Taq Hi-Fi kit (Invitrogen). Subsequently, the ORF of the aMPV-A or -B G gene was cloned into the intergenic region between the fusion (F) and hemagglutinin-neuraminidase (HN) genes in the pFLC-LaSota vector through a two-step subcloning process using the In-Fusion ® PCR cloning kit (Invitrogen). The resulting recombinant clones, designated as pLS/aMPV-A G and pLS/aMPV-B G, respectively, were amplified in Stbl2 cells at 30˚C for 24 hours and purified using a QIAprep Spin Miniprep kit (Qiagen). The sequences of primers used in the In-Fusion ® PCR cloning and G gene amplification are provided in Table 1 .
Virus Rescue and Propagation
Rescue of the recombinant LaSota/aMPV-A or -B G virus was performed by transfection of the full-length cDNA clones and supporting plasmids into HEp-2 cells as described previously [31] . The rescued viruses, which were confirmed by a positive hemagglutination assay (HA) [32] , were plaque purified three times in DF-1 cells and finally amplified in SPF chicken embryos three times. The AF was harvested, aliquoted, and stored at −80˚C as a stock. The complete genomic sequences of the rescued viruses were determined by direct sequencing of the RT-PCR products amplified from the viral genomic RNA as described previously [30] .
Figure 1. Schematic representation of pLS/aMPV-AG and -BG construction. The open reading frame of the G gene of aMPV-A or -B, amplified from virus genomic RNA, was cloned into the intergenic region between the F and HN genes in the pFLC-LaSota vector through a two-step process using the In-Fusion ® PCR cloning kit (Invitrogen). The NDV Gene Start and Gene End signal sequences and the aMPV-
Virus Titration, Pathogenicity, and Growth Dynamics Assays
Analysis of the recombinant viral stock titers, rLS/ aMPV-A G and rLS/aMPV-B G, were completed using the standard HA test in a 96-well microplate, the 50% tissue infectious dose (TCID 50 ) assay on DF-1 cells, and the 50% egg infective dose (EID 50 ) assay in 9-day-old SPF chicken embryos and compared to the parental LaSota virus [32] . Pathogenicity of the recombinant viruses was assessed by performing the standard mean death time (MDT) and intracerebral pathogenicity index (ICPI) tests and also compared to the parental LaSota virus [32] . Cytopathic effects (CPE) and growth dynamics of the recombinant viruses were examined in DF-1 cells and compared to the parental virus as described previously [30] .
Immunofluorescence Assay (IFA)
Expression of the G protein from DF-1 cells infected with the rLS/aMPV-B G recombinant virus was examined by IFA with anti-aMPV-B chicken serum (kindly provided by Dr. Silke Rautenschlein, University of Vet. Med. Hannover) as described previously [30] . Fluorescence was examined and digitally photographed using an inverted fluorescence microscope at 100X magnifications with matching excitation/emission filters for FITC or Alexa Fluor ® 568 (Nikon, Eclipse Ti, Melville, NY).
Immunization and Challenge Experiments
Seventy one-day-old SPF turkey poults were randomly divided into seven groups of 10 birds each and housed in Horsfal isolators (Federal Designs, Inc., Comer, GA) with ad libitum access to feed and water in the SEPRL BLS-3E animal facility. Each bird in groups 1, 2 and 3 was inoculated with 100 µl PBS via intranasal (IN) and intraocular (IO) routes as controls. Birds in groups 4 and 5 were vaccinated with 100 µl of rLS/aMPV-A G (1.0 × 10 7 TCID 50 /ml), and birds in groups 6 and 7 were vaccinated with 100 µl of rLS/aMPV-B G (1.0 × 10 7 TCID 50 / ml) per bird via IN/IO routes. At 14 days post-vaccination (DPV), blood samples were collected from each bird to detect serum antibody responses against NDV and aMPV-A or B. Immediately after blood collection, the birds in groups 1, 4, and 6 were challenged with the velogenic NDV/CA02 virus with a dose of 10 5 EID 50 /bird via IN/IO routes as described previously [33] . Mortality of the NDV/CA02-challenged birds was monitored and recorded daily for two weeks. Birds in groups 2, 3, 5, and 7 were challenged with homologous pathogenic aMPV through transmission infection by direct contact with infected birds. Two-week-old SPF turkeys were infected with pathogenic aMPV-A or aMPV-B with a dose of 10 2 ID 50 /bird via IN/IO routes. Five of the aMPV-A or -B virus-infected turkeys were then placed into each corresponding group for the homologous aMPV challenge through direct-contact transmission. The co-mingled birds were monitored daily for clinical signs of aMPV disease for 14 days. Typical clinical signs of the aMPV disease were scored as follows; nasal exudates when squeezed (Score 1), nasal discharge (Score 2), and/or frothy eyes (Score 3), according to the scoring system of Cook et al. [34] . The clinical sign scores post-challenge were statistically analyzed using two-factor ANOVA with a 1% level of significance between each vaccine treatment and corresponding control group (Microsoft Excel). Tracheal swabs were collected from each aMPV-A or -B viruschallenged birds at 5, 7, and 9 days post-challenge (DPC) for detection of virus shedding.
Detection of Immunoresponse and Challenged Virus Shedding
The NDV-specific serum antibody response was determined using the standard hemagglutination inhibition (HI) test [32] and aMPV subtype-specific serum antibodies were determined by an enzyme-linked immunosorbent assay (ELISA) as described previously, except using sucrose-gradient purified aMPV-A or aMPV-B as an antigen [29, 30] . Virus replication or viral RNA shedding from turkey tracheal tissues following challenge with aMPV-A or -B virus was detected by RT-PCR using aMPV-A or -B N gene-specific primers ( Table 1) as described previously [29, 35] .
Results
Generation of the rLS/aMPV-A and -B G Virus
Two full-length cDNA clones encoding the complete anti-sense genome of the NDV LaSota vaccine strain and the G gene of aMPV-A or -B were constructed through RT-PCR and In-Fusion PCR cloning (Figure 1) . The insertion of the transcription "cassettes" containing NDV LaSota intergenic regions and the G gene ORF of aMPV-A or B increased the length of the recombinant clones by 1338 and 1410 nts, respectively. Thus, the total length of pLS/aMPV-A G and pLS/aMPV-B G is 16,524 and 16,596 nts, respectively, and is divisible by 6 abiding by the "Rule of Six" [36] . After co-transfection of the pLS/aMPV-A or -B G clone and supporting plasmids in HEp-2 cells and subsequent amplification in SPF chicken embryonated eggs, the LaSota strain-based recombinant viruses vectoring the G gene of aMPV-A or -B were rescued, purified and propagated. The fidelity of the rescued viruses was confirmed by sequence analysis 
Biological Characterization of the rLS/aMPV-A G and -B G Viruses
To determine if the additional foreign G gene affects virus replication of the recombinant rLS/aMPV-A and -B G viruses, pathogenicity and growth dynamics were examined in vitro and in vivo by conducting MDT and ICPI tests and titration assays. As shown in Table 2 , the recombinant viruses appeared to be slightly attenuated in day-old chickens with a lower ICPI (0.0) than the parental LaSota strain. The titers of the recombinant viruses grown in either embryonated eggs or in DF-1 cells, as measured by EID 50 , TCID 50 and HA, were comparable to the titers of the parental LaSota strain ( Table 2) . They were stable and did not show any apparent changes in MDT and virus titers after 10 passages in SPF chicken embryos (data not shown). In addition, cytopathic effects induced by the rLS/aMPV-A G virus infection were indistinguishable from those seen with the parental LaSota virus in infected DF-1 cells (Figure 2) . Finally, no significant differences in the growth kinetics between the rLS/aMPV-A G, rLS/aMPV-B G and the parental LaSota viruses was detected (Figure 3 ).
Expression of the G Protein by rLS/aMPV -B G
Expression of the G protein from aMPV-B G infected DF-1 cell was examined by IFA using chicken anti-aMPV-B serum and FITC-labeled goat anti-chicken IgG.
In addition, to pinpoint the location of the expressed G protein in relation to recombinant virus infected DF-1 cells, mouse anti-NDV HN monoclonal antibody (Mab) and Alexa Fluor ® 568 conjugated goat anti-mouse IgG were also used. As shown in Figure 4 , NDV LaSota infected cells were positively stained with mouse anti-NDV HN Mab and Alexa-conjugates, but not with chicken anti-aMPV-B serum and FITC conjugate (Figures  4(a) and (b) ), demonstrating the specificity of the antibodies and conjugates. When examining rLS/aMPV-B G infected DF-1 cells stained with a mixture of anti-aMPV-B/FITC and anti-NDV HN/Alexa 568 antibodies, both green (Figure 4(c) ) and red (Figure 4(d) ) fluorescence were observed by fluorescence microscopy. After merging both fluorescent images, green and red fluorescence co-localized to the same cells (Figure 4(f) ), which corresponded to viral CPE observed in the same field (Figure 4(e) ). This result confirms that the aMPV-B G protein is co-expressed with the NDV HN protein from the recombinant virus in the infected cells.
Immune Response and Protection against Challenge
All turkeys that were immunized with either rLS/aMPV-A G or B G virus produced high NDV-specific HI antibody titers ( Table 3 ) and were completely protected against NDV challenge without showing any clinical sign of disease ( Table 3) . In contrast, all of the birds in the unvaccinated control group (inoculated with PBS) displayed typical clinical signs of conjunctivitis and severe depression from 2 to 4 DPC and 100% mortality by 5 DPC. After challenging with the virulent aMPV-A or -B virus through transmission, turkey poults in the control groups (inoculated with PBS) exhibited typical clinical signs of the disease from 4 DPC, showing nasal exudates when squeezed (Score 1), nasal discharge (Score 2), and/or frothy eyes (Score 3) ( Figure 5 ). The infected birds showed peak clinical signs between 7 -9 DPC, which gradually decreased in severity thereafter, but at 14 DPC 20% -30% of infected birds still showed some clinical signs. In contrast, turkeys vaccinated with the rLS/aMPV-A G or -B G virus resulted in significantly less severe clinical signs than those in the corresponding control groups (Figure 5 , p < 0.01). Most vaccinated birds showed nasal exudates when squeezed or nasal discharge, however these milder clinical signs of the disease disappeared after 11 DPC (Figure 5) . Presence of aMPV subtype-specific antibodies in vaccinated turkey sera was not detected by ELISA (data not shown). Viral RNA shedding, or the presence of the challenge virus (aMPV-A or -B) in the tracheal lumen, was detected in 100% of the control birds at 5, 7, and 9 DPC (Table 4 ). Viral shedding of the challenge viruses from corresponding rLS/aMPV-A G or -B G vaccinated birds was somewhat less at 9 DPC when 50% and 70% of the birds were negative for viral RNA, respectively ( Table  4 ).
Discussion
In the present study, we generated and evaluated LaSota strain-based recombinant NDV viruses expressing the G protein of aMPV-A or-B as next-generation, bivalent vaccine candidates. The G protein of aMPV is thought to be responsible for attachment of the virus particles to the host cell surface receptors to initiate infection. However, the G deletion or truncation mutants of aMPV were viable in cell cultures, but attenuated in SPF turkeys and induced a weaker immune response than the wild-type virus [29, 37] , implying that the G protein may play a role in immunogenicity to the natural host. Thus, we selected the G protein to be expressed by the recombinant NDV vector to investigate the role of the G protein in inducing protective immunity against aMPV challenge, as well as the protective efficacy conferred by the NDV vector against an NDV challenge in turkeys.
Our results showed the safety, stability, and possible application of these recombinant vaccine candidates for use in young turkeys, the most vulnerable population to NDV and aMPV diseases [2, 22, 38] . Turkeys vaccinated with either rLS/aMPV-A G or -B G virus had comparable levels of NDV-specific HI antibody response and survived the lethal dose NDV challenge without any clinical sign of disease. To properly evaluate protective efficacy of these vaccine candidates against homologous aMPV challenge, the vaccinated and control birds were challenged with pathogenic aMPV-A or -B through transmission infection to mimic natural infection. It appeared that the infected birds, through transmission, showed clinical signs two days later than birds challenged directly via IN/IO routes, indicating aMPV had a two-day incubation period while spreading through the environment. At 9 DPC with pathogenic aMPV-A or -B, the recombinant virus-vaccinated turkeys showed milder clinical signs and less virus shedding than the birds in the control groups. The lack of detectable aMPV G genespecific antibody response and the partial protection conferred by the recombinant viruses against homologous aMPV challenge suggest that the aMPV G protein is a weak antigen. Our data on the aMPV G protein, inducing partial protective immunity, together with the findings by others on immunogenicity of individual aMPV structural proteins [18, 21] , demonstrates that a single aMPV protein may not have the capability to induce a strong enough immune response to provide complete protection against aMPV disease. It is reasonable to speculate that co-expression of two or more major structural proteins of the aMPV virus, i.e. the F, G and/or M proteins, perhaps by the NDV vector, may be necessary to induce an enhanced protective immunity against aMPV infection.
In summary, in the present study, we successfully generated NDV/aMPV-A G and -B G recombinant viruses. Turkeys vaccinated with these recombinant viruses were completely protected against velogenic NDV challenge and partially protected against homologous pathogenic aMPV challenge. The results suggest that the aMPV G protein is a weak antigen and other immunegenic components of the virus, most likely the F protein, may be needed and added to the recombinant LaSota vaccine vector in the future to improve the bivalent vac- cine protective efficacy against aMPV infections.
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